2020-07-002 - AtG - Angiotheragnostics: New treatment with its patient selection biomarker for patients with advanced kidney cancer
Contacts
LT
Acronim & Gínjol codes
AtG
2020-07-002
Main technology offer
Developing a new drug to prevent anti-angiogenic resistance. A patient selection biomarker kit to identify which patient will benefit from the treatment
Spin-off based on this technology
L'Hospitalet de Llobregat, Spain
2021
ATG THERAPEUTICS SL
Public Partners
Readiness Level
3-4 Experimental PoC /
5 Prototype /
6-7 MVP /
8 Industrialization /
9 Commercialization
MIN
1
2
3
4
5
6
7
8
9
10
MAX
MIN
1
2
3
4
5
6
7
8
9
10
MAX
MIN
1
2
3
4
5
6
7
8
9
10
MAX
Impact: ESG & SDG Goals
Health and Safety: Personalized Medicine. Our goal is to offer more efficient and less toxic therapeutic options for the treatment of cancer therapeutic resistance
-
Market Data
Anti-angiogenic drugs are used as a first line of treatment for different tumor types (kidney, liver, colorectal, ovarian, lung and neuroendocrine tumors), block the formation of new blood vessels and prevent tumor growth and progression. However, clinical evidence reports resistance to treatment in almost 100% of patients. Until now, resistant patients have no established and proven alternative therapeutic possibility. The main objective is build a pipeline of tumor adaptation inhibitors and biomarkers to stop cancer growth over time.
0
0
0
ATG Tx is a growing spin-off, looking for Fundraising for developing clinical trials.
Lead indication mRCC is an Orphan Disease. 2027 Global Market for RCC (Renal Cell Carcinoma): 600.000 with a 30% corresponding to mRCC. 60% need biomarker: 90.000 patients/year with a $6.67B/year worldwide total market value. Our technology can be applied to other tumors too like: Pancreatic neuroendocrine tumors ($1.5B/y), Hepatocellular carcinoma ($1.4B/y) or colorectal cancer ($10.8B/y).
Patients with advanced cancer in: - Metastatic Renal Cell Carcinoma - Pancreatic neuroendocrine tumors - Hepatocellular carcinoma - Colorectal cancer
Funding
7 Mio€ for the development of clinical trials for best-in-class inhibitor against our target.
Enable us to select the best-in-class pre-clinical TA-1 inhibitor candidate by Q42024, advance the development of the biomarker against TA-1 and validate 2 additional targets in our pipeline (TA-2 and TA-3). This will bring us to a strong position to raise our Series A.
1. Selection of best-in-class inhibitor against our target 2. Pre-clinical data and toxicology 3. Development of Biomarkers against our targets 4. Validation of 2 additional targets in our pipeline.
Technology Status
The science is based on our unique ability to identify cancer molecular vulnerabilities, with unique animal models which have a high genetic overlap with human cancers, and the ability to assess response and adaptation to treatment with high reproducibility of clinical response observed in patients. This platform identifies treatment induced escape mechanisms in resistance to treatment that are also applicable to naïve tumors.
Funds needed for the development of clinical trials
Roadmap defined in 3 phases: Selection of best-in-class inhibitor against our target, pre-clinical phase, and a last first in human planning.
Package of 3 patents, being the last one issued in 2023: - EP15382109.5 (2015) - EP20382600.3 (2020) - EP23382217.0 (2023)
-
Additional information
Patents: WO2016142471A1 - Dec 15th, 2016 - Status: Granted -
Innovate and solve the existing medical need in patients resistant to anti-angiogenic therapies